Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atezolizumab for previously treated advanced thymic carcinoma (China, phase II)
CTR20192573Phase 2Terminated
- Sponsor
- Roche
- Start
- Jan 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of atezolizumab in thymic carcinoma (TC), sponsored by Roche. Started Jan 2020; status: terminated.
02
Drugs
atezolizumab
03
Conditions
thymic carcinoma (TC)
Beyond the preview
Go deeper on CTR20192573.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20192573.